Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Nanobiotix S.A.

Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is one rooted in designing pioneer physical based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges.   

Nanobiotix’s novel first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Furthermore, Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies. 

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Company’s headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany. More: www.nanobiotix.com

Bpifrance

European Investment Bank

Johnson & Johnson Innovation – JJDC

Amorçage Rhône Alpes

Apicap

Karista

Matignon Technologies

Seventure Partners

Crédit Mutuel Innovation

Nanobiotix

LianBio, partenaire de Nanobiotix, transfère ses droits de développement et de commercialisation de NBTXR3 en Chine et sur d'autres marchés asiatiques. PR : https://lnkd.in/e6ATUM7T

Nanobiotix partner LianBio assigns its development and commercialization rights for NBTXR3 in China and other Asian Markets. PR link: https://lnkd.in/eE6vkSkq

Avec toute notre gratitude pour votre soutien afin de révolutionner le traitement de millions de patients à travers le monde, nous vous souhaitons de joyeuses fêtes à tous !

With gratitude for your support in revolutionizing treatment for millions of patients, we offer happy holidays to all!

Happy Thanksgiving to all of our friends, colleagues, supporters and patients in the United States. We are inspired by the spirit of Thanksgiving as we reflect on the important progress our incredible team has achieved this year toward achieving our mission of revolutionizing treatment for millions. Best wishes and enjoy the holiday!

msh id	COM:NANOBIOTIX
symbol	NANO
name	Nanobiotix S.A.
homepage url	https://www.nanobiotix.com
country	FR
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	102
crunchbase url	-
linkedin url	-
founders	-

market cap	257.09M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	25.16
growth score 28	69.12
growth score 90	80.92
growth score 365	76.53

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:NANOBIOTIX

Nanobiotix

Last Close

3.58

21/11 16:35

Market Cap

237.91M

Beta: -

Volume Today

42.60K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-